Stimulation of Vascular Dopamine Receptors: Status and Future Strategies

References

• Goldberg L. I., Volkman P. H., Kohli J. D. A comparison of the vascular dopamine receptor with other dopamine receptors. Ann. Rev. Pharmacol. Toxicol. 1978; 18: 57–79
   PubMed Web of Science ®Google Scholar
• Hahn R. A., Wardell J. R., Sarau H. M., Ridley P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine agonist. J. Pharmacol. Exp. Ther. 1982; 233: 305–313
   Google Scholar
• Ohlstein E. H., Zabko-Potapovich B., Berkowitz B. A. Studies on vascular dopamine receptors with the dopamine receptor agonist-SK&F 82526. J. Pharmacol. Exp. Ther. 1984; 229: 433–439
   PubMed Web of Science ®Google Scholar
• Langer S. Z. Presynaptic regulation of the release of catecholamines. Pharmacol. Rev. 1980; 32: 337–362
   PubMed Web of Science ®Google Scholar
• Ensinger H., Majewski H., Hedler L., Starke K. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits. J. Pharmacol. Exp. Ther. 1985; 234: 681–690
   PubMed Web of Science ®Google Scholar
• Lokhandwala M. F., Barret R. J. Dopamine receptor agonists in cardiovascular therapy. Drug Devel. Res. 1983; 3: 229–310
   Web of Science ®Google Scholar
• Sengupta S., Lokhandwala M. F. Characterization of the hypotensive action of dopamine receptor agonists fenoldopam and quinoprole in anaesthetized rats. J. Auton. Pharmacol. 1985; 5: 289–294
   PubMedGoogle Scholar
• Hieble J. P., Owen D. A., Harvey C. A., Blumberg A. L., Valocik R. E., DeMarinis R. M. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog. 1987, This volume
   Google Scholar
• Lokhandwala M. F., Barret R. J. Dopamine receptor agonists and hypertension. Dopamine Receptor Agonists, G. Poste, S. T. Crooke. Plenum Press, New York 1984; 209–223
   Google Scholar
• Williams J. L., Buylaent W. A., Lefebvre R. A., Bogaert M. G. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol. Rev. 1985; 37: 165–216
   PubMed Web of Science ®Google Scholar
• Lokhandwala M. F., Watkins H. O., Sabouni M. H., Alkadhi K. A. Pharmacological analysis of the actions of SK&F 82526 on cardiovascular dopamine receptors. J. Pharmacol. Exp. Ther. 1985; 234: 337–344
   PubMed Web of Science ®Google Scholar
• Sabouni M. H., Alkadhi K. A., Lokhandwala M. F. Pharmacological characterization of dopamine receptors in the stellate ganglia with selective DA1 and DA2 receptor agonists and antagonists. J. Pharmacol. Exp. Ther. 1986; 236: 65–70
   PubMed Web of Science ®Google Scholar
• Goldberg L. I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol. Rev. 1972; 24: 1–29
   PubMed Web of Science ®Google Scholar
• Rajfer S. I., Anton A. H., Rossen J. D., Goldberg L. I. Beneficial hemodynamic effects of oral levodopa in heart failure. N. Eng. J. Med. 1984; 310: 1357–1362
   PubMed Web of Science ®Google Scholar
• Berkowitz B. A., Ohlstein E. H. Fenoldopam. Drug Dev. Res. 1986, In press
   Google Scholar
• Lappe R., Todt J., Wendt R. Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1986; 236: 187–191
   PubMed Web of Science ®Google Scholar
• Stote R., Dubb J., Familiar R., Erb B., Alexander F. A new oral renal vasodilator SK&F 82526. Clin. Pharmacol. Ther. 1983; 34: 309–315
   PubMed Web of Science ®Google Scholar
• Flaim K. E., Gessner G. M., Crooke S. T., Sarau H. M., Weinstock J. Binding of a novel dopaminergic agonist radioligand [3H]fenoldopam (SK&F 82526) to D-1 receptors in rat striatum. Life Sci. 1985; 36: 1427–1436
   PubMed Web of Science ®Google Scholar
• Ohlstein E. H., Zabko-Potapovich B., Berkowitz B. The DA1 receptor agonist fenoldopam (SK&F 82526) is also an alpha-2 adrenoceptor antagonist. Eur. J. Pharmacol. 1985; 118: 321–329
   PubMed Web of Science ®Google Scholar
• McCoy C. E., Douglas F. L., Goldberg L. I. Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats. Hypertension 1986; 8: 298–302
   PubMed Web of Science ®Google Scholar
• Harvey J. N., Worth D. P., Brown J., Lee M. R. The effect of fenoldopam (SK&F 82526-J) a peripheral dopamine receptor agonists on blood pressure and renal function in normal man. Br. J. Clin. Pharmacol. 1985; 19: 21–27
   PubMed Web of Science ®Google Scholar
• Harvey J. N., Worth D. P., Brown J., Lee M. R. Studies with fenoldopam a dopamine receptor DA1 agonist in essential hypertension. Br. J. Clin. Pharmacol. 1986; 21: 53–61
   PubMed Web of Science ®Google Scholar
• Ventura H. A., Messerli F. H., Frohlich E. P., Kobrin I., Oigman W., Dunn F. G. Immediate hemodynamic effects of a dopamine receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 1984; 69: 1142–1145
   PubMed Web of Science ®Google Scholar
• Carey R. M., Stote R., Dubb J. W., Townsend L. H., Rose C. E., Jr., Kaiser D. L. Selective peripheral dopamine −1 receptor stimulation with fenoldopam in human essential hypertension. J. Clin. Invest. 1984; 74: 2198–2207
   PubMed Web of Science ®Google Scholar
• McCoy C., Frederickson E., Murphy M., Kotake A., Douglas F., Goldberg L. I. Effects of dopamine (DA1) receptor agonist administration in hypertensive patients. Hypertension 1985; 7: 848
   Web of Science ®Google Scholar
• Young J. B., Leon C. A., Pratt C. M., Suarez J. M., Aronoff R. D., Roberts R. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. J. Am. Coll. Cardiol. 1985; 6: 792–796
   PubMed Web of Science ®Google Scholar
• Foley J. J., Sarau H. M. Adrenergic binding studies of SK&F 82526 and its enantiomers. Fed. Proc. 1984; 43: 555
   Google Scholar
• Hidaka H., Nagatsu T., Takeya K., Takeuchi R., Suda H., Kojini K., Matsuzaki M., Umezawa H. Fusaric acid, a hypotensive agent produced by fungi. J. Antibiotics 1969; 22: 228–230
   PubMed Web of Science ®Google Scholar
• Hidaka H., Takaya A. Decreased blood pressure by halobutylpicolinic acid, an inhibitor of dopamine β-hydroxylase. Nature 1972; 239: 334–335
   PubMed Web of Science ®Google Scholar